Trinovopan: Pre-Clinical Development of a Novel Anti-Cancer Combinational Therapy
Linda Wei
Sir Winston Churchill
Floor Location : S 194 H

Each year, cancer accounts for about 7 million deaths, an estimated 12% of the global mortality figure. Leukemia, in particular T-cell acute lymphoblastic leukemia, has one of the highest mortality rates of any cancer, becoming lethal in more than 80% of all cases annually. Standard forms of treatment involving chemotherapy and radiation have been generally successful upon early diagnosis; however, there are an increasing number of cases where conventional treatment fails to eradicate lymphoblasts. rnrnTrinovopan is a novel anticancer drug that aims to unite the strengths of an herbal combination to provide an alternative to such conventional therapies. In this pre-clinical investigation of Trinovopan, varying dosages and combinations of the drug were tested on the Jurkat strain of T-ALL cells in an effort to determine the optimal composition, dosage, and treatment timeframe for Trinovopan. rnrnA combination of experimentation and research has determined Trinovopan to be a potent anti-cancer agent due to the highly synergistic effects of its components. Moreover, Trinovopan induces cancerous cell apoptosis through methylanthraquinone-induced caspase activation, with marked apoptotic rates for T-cell acute leukemia. These results cast a positive light on this novel treatment, suggesting it should be a well-balanced and safe alternative to harmful conventional treatments in the early stages of cancer. They give us hope that Trinovopan may be the key to overcoming cancer in the near future.